GB0700058D0 - Anti-tumor vaccine based on normal cells - Google Patents

Anti-tumor vaccine based on normal cells

Info

Publication number
GB0700058D0
GB0700058D0 GBGB0700058.1A GB0700058A GB0700058D0 GB 0700058 D0 GB0700058 D0 GB 0700058D0 GB 0700058 A GB0700058 A GB 0700058A GB 0700058 D0 GB0700058 D0 GB 0700058D0
Authority
GB
United Kingdom
Prior art keywords
normal
composition
cells
lymphoid cells
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0700058.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCANCELL APS
Original Assignee
SCANCELL APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCANCELL APS filed Critical SCANCELL APS
Priority to GBGB0700058.1A priority Critical patent/GB0700058D0/en
Publication of GB0700058D0 publication Critical patent/GB0700058D0/en
Priority to HR20110899T priority patent/HRP20110899T1/hr
Priority to AU2008203730A priority patent/AU2008203730B2/en
Priority to EP08701232A priority patent/EP2102331B1/en
Priority to ES08701232T priority patent/ES2372713T3/es
Priority to US12/522,048 priority patent/US10023839B2/en
Priority to DK08701232.4T priority patent/DK2102331T3/da
Priority to PL08701232T priority patent/PL2102331T3/pl
Priority to PCT/EP2008/050050 priority patent/WO2008081035A1/en
Priority to SI200830447T priority patent/SI2102331T1/sl
Priority to JP2009544412A priority patent/JP5452231B2/ja
Priority to AT08701232T priority patent/ATE522600T1/de
Priority to PT08701232T priority patent/PT2102331E/pt
Priority to CY20111101112T priority patent/CY1112668T1/el
Priority to US15/707,474 priority patent/US20180036397A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0700058.1A 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells Ceased GB0700058D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0700058.1A GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells
PT08701232T PT2102331E (pt) 2007-01-03 2008-01-03 Vacina antitumoral derivada de células cd4+ normais modificadas quimicamente
DK08701232.4T DK2102331T3 (da) 2007-01-03 2008-01-03 Anti-tumorvaccine afledt af normale kemisk modificerede CD4 -celler
PCT/EP2008/050050 WO2008081035A1 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cells
EP08701232A EP2102331B1 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cd4+ cells
ES08701232T ES2372713T3 (es) 2007-01-03 2008-01-03 Vacuna antitumoral derivada de celulas cd4+ normales modificadas químicamente.
US12/522,048 US10023839B2 (en) 2007-01-03 2008-01-03 Anti-tumour vaccine derived from normal cells
HR20110899T HRP20110899T1 (hr) 2007-01-03 2008-01-03 Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+
PL08701232T PL2102331T3 (pl) 2007-01-03 2008-01-03 Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
AU2008203730A AU2008203730B2 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cells
SI200830447T SI2102331T1 (sl) 2007-01-03 2008-01-03 Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic
JP2009544412A JP5452231B2 (ja) 2007-01-03 2008-01-03 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
AT08701232T ATE522600T1 (de) 2007-01-03 2008-01-03 Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen
CY20111101112T CY1112668T1 (el) 2007-01-03 2011-11-17 Εμβολιο εναντι ογκων που προκυπτει απο φυσιολογικα χημικως τροποποιημενα cd4+ κυτταρα
US15/707,474 US20180036397A1 (en) 2007-01-03 2017-09-18 Anti-tumor vaccine derived from normal cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700058.1A GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells

Publications (1)

Publication Number Publication Date
GB0700058D0 true GB0700058D0 (en) 2007-02-07

Family

ID=37759205

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0700058.1A Ceased GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells

Country Status (14)

Country Link
US (2) US10023839B2 (https=)
EP (1) EP2102331B1 (https=)
JP (1) JP5452231B2 (https=)
AT (1) ATE522600T1 (https=)
AU (1) AU2008203730B2 (https=)
CY (1) CY1112668T1 (https=)
DK (1) DK2102331T3 (https=)
ES (1) ES2372713T3 (https=)
GB (1) GB0700058D0 (https=)
HR (1) HRP20110899T1 (https=)
PL (1) PL2102331T3 (https=)
PT (1) PT2102331E (https=)
SI (1) SI2102331T1 (https=)
WO (1) WO2008081035A1 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801751A1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
US8666674B2 (en) 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
JP5816627B2 (ja) * 2009-10-27 2015-11-18 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
GB201013443D0 (en) 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
MX388325B (es) 2015-05-28 2025-03-19 Kite Pharma Inc Metodos de diagnostico para tratamiento con linfocitos t.
IL295224B2 (en) 2015-05-28 2025-07-01 Kite Pharma Inc Methods of conditioning patients for t cell therapy
EP3364969A4 (en) 2015-10-20 2019-07-10 Kite Pharma, Inc. METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
CN109414455B (zh) 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
PT3583129T (pt) 2017-02-14 2021-12-14 Kite Pharma Inc Moléculas de ligação a cd70 e seus métodos de uso
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
AU2018250148B2 (en) 2017-04-03 2021-09-23 Kite Pharma, Inc. Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
SG10201912400VA (en) 2017-04-24 2020-02-27 Kite Pharma Inc Humanized antigen-binding domains against cd19 and methods of use
TWI862477B (zh) 2017-05-26 2024-11-21 美商凱特製藥公司 製備和使用胚胎間充質先驅細胞的方法
KR20230052312A (ko) 2017-09-15 2023-04-19 카이트 파마 인코포레이티드 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
CA3084470A1 (en) 2017-10-18 2019-04-25 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
BR112020014446A2 (pt) 2018-01-15 2020-12-29 Pfizer Inc. Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
TWI784324B (zh) 2018-04-12 2022-11-21 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體t細胞治療
KR102544086B1 (ko) 2018-06-01 2023-06-16 카이트 파마 인코포레이티드 키메라 항원 수용체 t 세포 요법
US20210155941A1 (en) 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
SG11202101014XA (en) 2018-08-02 2021-02-25 Kite Pharma Inc Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
US20220175900A1 (en) * 2019-04-12 2022-06-09 Cytovac A/S Method for preparation of cancer/testis antigen-specific t-cells
US20200384027A1 (en) 2019-05-03 2020-12-10 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
KR20220054383A (ko) 2019-09-03 2022-05-02 알로젠 테라퓨틱스 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
US20220155299A1 (en) 2020-10-28 2022-05-19 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
AU2021410635A1 (en) 2020-12-24 2023-06-29 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
WO2022150582A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
EP4281545A1 (en) 2021-01-21 2023-11-29 CytoVac A/S Method for t-cell expansion and related medical applications
TW202241469A (zh) 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
IL305571A (en) 2021-03-11 2023-10-01 Kite Pharma Inc Improving the function of immune system cells
AU2022259428A1 (en) 2021-04-16 2023-10-26 Kite Pharma, Inc. Taci/bcma dual binding molecules
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
EP4337227A2 (en) 2021-05-14 2024-03-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
IL308696A (en) 2021-05-24 2024-01-01 Kite Pharma Inc Nkg2d-based chimeric antgen receptor
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
WO2022269019A1 (en) 2021-06-25 2022-12-29 Cytovac A/S Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells
WO2023278553A1 (en) 2021-07-01 2023-01-05 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
JP2024525485A (ja) 2021-07-02 2024-07-12 カイト ファーマ インコーポレイテッド 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
WO2023009989A1 (en) 2021-07-26 2023-02-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
US20230268031A1 (en) 2021-07-30 2023-08-24 Kite Pharma, Inc. Monitoring and management of cell therapy-induced toxicities
TWI863006B (zh) 2021-10-18 2024-11-21 美商凱特製藥公司 用於嵌合抗原受體之信號傳導域
US20230296610A1 (en) 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2023247324A1 (en) 2022-06-24 2023-12-28 Cytovac A/S Novel combination treatment with adoptive cellular therapy
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
KR20250097844A (ko) 2022-10-28 2025-06-30 카이트 파마 인코포레이티드 면역요법의 효능 향상 및 지속적인 반응
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy
KR20250162836A (ko) 2023-03-17 2025-11-19 카이트 파마 인코포레이티드 종양 미세환경이 면역요법의 효능에 미치는 영향
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2025188561A1 (en) 2024-03-04 2025-09-12 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025231376A1 (en) 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car
US20260009001A1 (en) 2024-07-08 2026-01-08 Kite Pharma, Inc. Systems and methods for applying mechanical force to living cells to generate a phenotypic response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Also Published As

Publication number Publication date
JP5452231B2 (ja) 2014-03-26
US10023839B2 (en) 2018-07-17
PT2102331E (pt) 2011-12-19
WO2008081035A1 (en) 2008-07-10
HRP20110899T1 (hr) 2011-12-31
US20180036397A1 (en) 2018-02-08
CY1112668T1 (el) 2016-02-10
PL2102331T3 (pl) 2012-01-31
AU2008203730B2 (en) 2013-11-07
EP2102331A1 (en) 2009-09-23
DK2102331T3 (da) 2011-10-17
AU2008203730A1 (en) 2008-07-10
JP2010514455A (ja) 2010-05-06
SI2102331T1 (sl) 2012-01-31
EP2102331B1 (en) 2011-08-31
ATE522600T1 (de) 2011-09-15
ES2372713T3 (es) 2012-01-25
US20100092498A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
Vacchelli et al. Trial watch: Peptide vaccines in cancer therapy
Kumai et al. Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses
Melief et al. Therapeutic cancer vaccines
Liu et al. Telomerase in cancer immunotherapy
JP2010514455A5 (https=)
Alexandrescu et al. Immunotherapy for melanoma: current status and perspectives
EA202190587A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
BR112012023692A2 (pt) imunoterapias contra vários tumores, incluindo câncer gastrointestinal e gástrico
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
JP2015512866A5 (https=)
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
Liu et al. Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK)
Ren et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)
Arina et al. Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1–resistant tumors leading to tumor eradication
WO2008118369A3 (en) Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
JP2018522880A5 (https=)
Öhlschläger et al. The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
Lu et al. Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
MX2020011787A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
Yang et al. HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma
Izgi et al. Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice
Enk et al. Immunotherapy of malignant melanoma–basic principles and novel therapeutic approaches

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)